Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/SRPRA_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/SRPRA_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/SRPRA_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/SRPRA_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/SRPRA_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00066141 | Prostate | Tumor | SRP-dependent cotranslational protein targeting to membrane | 10/3246 | 26/18723 | 8.67e-03 | 3.76e-02 | 10 |
GO:0072594112 | Thyroid | PTC | establishment of protein localization to organelle | 244/5968 | 422/18723 | 1.18e-28 | 4.97e-26 | 244 |
GO:0006605113 | Thyroid | PTC | protein targeting | 180/5968 | 314/18723 | 6.81e-21 | 1.19e-18 | 180 |
GO:0090150112 | Thyroid | PTC | establishment of protein localization to membrane | 149/5968 | 260/18723 | 1.64e-17 | 1.59e-15 | 149 |
GO:0070972111 | Thyroid | PTC | protein localization to endoplasmic reticulum | 51/5968 | 74/18723 | 6.57e-11 | 2.30e-09 | 51 |
GO:007259918 | Thyroid | PTC | establishment of protein localization to endoplasmic reticulum | 31/5968 | 46/18723 | 8.06e-07 | 1.24e-05 | 31 |
GO:004504716 | Thyroid | PTC | protein targeting to ER | 28/5968 | 42/18723 | 3.83e-06 | 4.80e-05 | 28 |
GO:00066126 | Thyroid | PTC | protein targeting to membrane | 64/5968 | 131/18723 | 3.67e-05 | 3.41e-04 | 64 |
GO:000661313 | Thyroid | PTC | cotranslational protein targeting to membrane | 19/5968 | 31/18723 | 7.02e-04 | 4.39e-03 | 19 |
GO:007259429 | Thyroid | ATC | establishment of protein localization to organelle | 247/6293 | 422/18723 | 2.88e-26 | 1.40e-23 | 247 |
GO:000660533 | Thyroid | ATC | protein targeting | 180/6293 | 314/18723 | 3.54e-18 | 4.39e-16 | 180 |
GO:009015031 | Thyroid | ATC | establishment of protein localization to membrane | 150/6293 | 260/18723 | 1.05e-15 | 7.96e-14 | 150 |
GO:007097232 | Thyroid | ATC | protein localization to endoplasmic reticulum | 53/6293 | 74/18723 | 2.52e-11 | 8.69e-10 | 53 |
GO:007259931 | Thyroid | ATC | establishment of protein localization to endoplasmic reticulum | 32/6293 | 46/18723 | 6.68e-07 | 9.13e-06 | 32 |
GO:004504722 | Thyroid | ATC | protein targeting to ER | 28/6293 | 42/18723 | 1.21e-05 | 1.17e-04 | 28 |
GO:000661212 | Thyroid | ATC | protein targeting to membrane | 64/6293 | 131/18723 | 2.11e-04 | 1.39e-03 | 64 |
GO:000661321 | Thyroid | ATC | cotranslational protein targeting to membrane | 19/6293 | 31/18723 | 1.45e-03 | 7.47e-03 | 19 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SRPRA | SNV | Missense_Mutation | | c.219C>G | p.Ile73Met | p.I73M | P08240 | protein_coding | deleterious(0.04) | possibly_damaging(0.606) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
SRPRA | SNV | Missense_Mutation | | c.175G>A | p.Asp59Asn | p.D59N | P08240 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
SRPRA | SNV | Missense_Mutation | | c.787N>G | p.Thr263Ala | p.T263A | P08240 | protein_coding | tolerated(0.59) | benign(0) | TCGA-BH-A1EV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
SRPRA | SNV | Missense_Mutation | rs778409990 | c.1385N>C | p.Val462Ala | p.V462A | P08240 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C8-A12M-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SRPRA | SNV | Missense_Mutation | | c.1864N>A | p.Asp622Asn | p.D622N | P08240 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-C8-A12T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SRPRA | SNV | Missense_Mutation | rs370707916 | c.1867N>G | p.Leu623Val | p.L623V | P08240 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-E9-A22E-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphane | SD |
SRPRA | SNV | Missense_Mutation | | c.583N>T | p.Pro195Ser | p.P195S | P08240 | protein_coding | tolerated(0.21) | benign(0) | TCGA-EW-A1P3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
SRPRA | insertion | Frame_Shift_Ins | novel | c.1419_1420insTCCCTTTACAACTTGA | p.Ala474SerfsTer23 | p.A474Sfs*23 | P08240 | protein_coding | | | TCGA-A8-A090-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SRPRA | insertion | Frame_Shift_Ins | novel | c.1829_1830insTGTCTTCAGTGTAGTACAAAGGCAGAGTGAGGGGGCTTGTGGCT | p.Ile611ValfsTer41 | p.I611Vfs*41 | P08240 | protein_coding | | | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SRPRA | SNV | Missense_Mutation | rs558045090 | c.391N>T | p.Arg131Cys | p.R131C | P08240 | protein_coding | deleterious(0) | benign(0.052) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |